Known targets — ChEMBL curated mechanism
GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHMGCRMMP1MMP13MMP7MMP8PTGS1PTGS2ileSpolrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 5/20 | 0.57 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.54 |
| ▸ | CASP2 | P42575 | 1/20 | 0.53 |
| ▸ | NAAA | Q02083 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.48 |
| ▸ | SELP | P16109 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL688390 | 1.00 | FAAH (0.57) | FAAHDNM1CASP2NAAAALDH1A1 | |
| SCHEMBL4408168 | 0.97 | FAAH (0.54) | FAAHDNM1CASP2NAAAALDH1A1 | |
| SCHEMBL9362964 | 0.97 | FAAH (0.57) | FAAHDNM1CASP2NAAAALDH1A1 | |
| SCHEMBL5949791 | 0.97 | FAAH (0.57) | FAAHDNM1CASP2NAAAALDH1A1 | |
| SCHEMBL9713447 | 0.97 | FAAH (0.57) | FAAHDNM1CASP2NAAAALDH1A1 | |
| SCHEMBL9846725 | 0.97 | FAAH (0.57) | FAAHDNM1CASP2NAAAALDH1A1 | |
| Potassium Ion SCHEMBL6756201 | 0.97 | FAAH (0.57) | FAAHDNM1CASP2NAAAALDH1A1 | |
| SCHEMBL9327574 | 0.97 | FAAH (0.57) | FAAHDNM1CASP2NAAAALDH1A1 | |
| SCHEMBL9362951 | 0.97 | FAAH (0.57) | FAAHDNM1CASP2NAAAALDH1A1 | |
| SCHEMBL29004803 | 0.89 | FAAH (0.58) | FAAHDNM1CASP2NAAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 251 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3562464-B1 | COMPOSITIONS COMPRISING TAURATE SURFACTANTS AND METHODS OF USING THE COMPOSITIONS | COLGATE PALMOLIVE CO (US) | 2024-10-09 | — | — | EP | claimed |
| JP-6192034-A | — | — | None | — | — | JP | disclosed |
| CN-122005622-A | Composition for improving, preventing or treating vaginitis or vulvitis comprising lactobacillus salivarius HHuMin-U | 比菲德股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-12616730-B2 | Topical composition comprising an extract of combined herbs comprising longanae arillus for the treatment or alleviation of skin ulcer and the use thereof | MEDIHELPLINE CO., LTD (KR) | 2026-05-05 | — | — | US | disclosed |
| US-12357553-B2 | Composition for treating hair loss or promoting hair growth, comprising piperonylic acid | Hesed Bio Co., Ltd. (KR) | 2025-07-15 | — | — | US | disclosed |
| US-20250082592-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION, ALLEVIATION OR TREATMENT OF SARCOPENIA, CONTAINING ROR-alpha ACTIVATOR JC1-40 | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2025-03-13 | — | — | US | disclosed |
| US-20250057872-A1 | INNATE IMMUNOMODULATORY EFFECT OF GINSENG BERRY POLYSACCHARIDES IN IMMUNOCOMPROMISED CONDITIONS | Gangneung-Wonju National University Industry Academy Cooperation Group (KR) | 2025-02-20 | — | — | US | disclosed |
| US-20250032385-A1 | FUNCTIONAL COMPOSITION FOR ALOPECIA COMPRISING CENTIPEDA MINIMA-DERIVED EXTRACT | D-NATURE CO., LTD. (KR) | 2025-01-30 | — | — | US | disclosed |
| EP-4186516-B1 | PHARMACEUTICAL COMPOSITION COMPRISING GRAPHENE QUANTUM DOTS FOR USE IN THE TREATMENT OF VIRAL DISEASES CAUSED BY ADENOVIRUS INFECTIONS | BIOGRAPHENE INC (KR) | 2024-12-11 | — | — | EP | disclosed |
| US-20240398692-A1 | MANUFACTURING METHOD OF COFFEE CELL AND ADVENTITIOUS ROOT CULTURE COMPRISING INCREASED BIOACTIVE SUBSTANCES AND USE THEREOF | BIO-FD&C (KR) | 2024-12-05 | — | — | US | disclosed |
| EP-1159952-A1 | COSMETICS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-12-05 | — | — | EP | disclosed |
| EP-0445785-B1 | Plate-like barium sulfate and cosmetic composition | KAO CORP (JP) | 1995-08-09 | — | — | EP | disclosed |
| EP-0455018-B1 | Pigment consisting of polyvalent metal salt of amidosulfonic acid and cosmetic composition containing the same | KAO CORP (JP) | 1994-09-07 | — | — | EP | disclosed |
| US-5340582-A | Crystal structure, optical characteristics | KAO CORPORATION (JP) | 1994-08-23 | — | — | US | disclosed |
| JP-H06192034-A | COSMETIC | KAO CORP | 1994-07-12 | — | — | JP | disclosed |
| US-5262148-A | HEATING A BARIUM SALT AND A SULFATE UNDER ACIDIC CONDITIONS TO REACT, FORMING BARIUM SULFATE HAVING A PLATE CRYSTAL STRUCTURE | KAO CORPORATION (JP) | 1993-11-16 | — | — | US | disclosed |
| US-5171572-A | BARIUM SULFATE AND COSMETIC COMPOSITIONS COMPRISING SAME | KAO CORPORATION (JP) | 1992-12-15 | — | — | US | disclosed |
| US-5167709-A | Improved spreadability | KAO CORPORATION (JP) | 1992-12-01 | — | — | US | disclosed |
| EP-0455018-A1 | Pigment consisting of polyvalent metal salt of amidosulfonic acid and cosmetic composition containing the same | KAO CORPORATION (JP) | 1991-11-06 | — | — | EP | disclosed |
| EP-0445785-A1 | Plate-like barium sulfate and cosmetic composition | KAO CORPORATION (JP) | 1991-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250082592-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION, ALLEVIATION OR TREATMENT OF SARCOPENIA, CONTAINING ROR-alpha ACTIVATOR JC1-40 | TFAM, RORA, CKMT1A; CKMT1B | FAAH 4759/4885DNM1 261/4885CASP2 3721/4885 |
| US-20250032385-A1 | FUNCTIONAL COMPOSITION FOR ALOPECIA COMPRISING CENTIPEDA MINIMA-DERIVED EXTRACT | BTN3A1, NGF, BBC3 | FAAH 190/4885DNM1 4385/4885CASP2 1432/4885 |
| US-12357553-B2 | Composition for treating hair loss or promoting hair growth, comprising piperonylic acid | EGFR, PDGFA, HGF | FAAH 626/4885DNM1 4032/4885CASP2 1780/4885 |
| US-12616730-B2 | Topical composition comprising an extract of combined herbs comprising longanae arillus for the treatment or alleviation of skin ulcer and the use thereof | CUTA, VEGFA, MMP8 | FAAH 1807/4885DNM1 981/4885CASP2 2021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.